US Stock MarketDetailed Quotes
ADAP Adaptimmune Therapeutics
- 1.075
- +0.015+1.42%
Close Apr 26 16:00 ET
- 1.090
- +0.015+1.40%
Post 19:36 ET
274.73MMarket Cap-1990P/E (TTM)
1.095High1.030Low1.16MVolume1.060Open1.060Pre Close1.24MTurnover0.68%Turnover RatioLossP/E (Static)255.56MShares2.05052wk High6.94P/B183.11MFloat Cap0.42052wk Low--Dividend TTM170.34MShs Float21.570Historical High--Div YieldTTM6.13%Amplitude0.420Historical Low1.065Avg Price1Lot Size
Adaptimmune Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 0.63%-140.88M | -818.71%-14.68M | 6.23%-45.16M | -6.09%-43.76M | 31.47%-37.28M | -1,421.36%-141.77M | -98.48%2.04M | -6.55%-48.16M | -31.13%-41.25M | -16.89%-54.4M |
| Net income from continuing operations | 31.18%-113.87M | -63.82%-47.92M | -10.09%-45.6M | 51.96%-21.39M | 102.06%1.04M | -4.66%-165.46M | 24.73%-29.25M | 2.31%-41.42M | -13.96%-44.52M | -33.11%-50.27M |
| Operating gains losses | 108.12%198K | -911.11%-511K | 113.87%332K | -236.76%-186K | 330.74%563K | -551.48%-2.44M | -91.63%63K | -4,531.48%-2.39M | 108.97%136K | -119.54%-244K |
| Depreciation and amortization | 61.98%9.84M | 99.79%2.87M | 93.96%2.89M | 43.81%2.23M | 15.67%1.85M | -7.49%6.08M | -35.68%1.44M | 2.54%1.49M | 7.55%1.55M | 11.07%1.6M |
| Other non cash items | -2,781.62%-21.88M | -268.63%-86K | -268.89%-304K | -6,024.93%-21.63M | -39.09%134K | -30.43%816K | 104.78%51K | -78.52%180K | 257.84%365K | -83.06%220K |
| Change In working capital | -1,529.78%-24.95M | 11.17%28.28M | 54.01%-4.7M | -31.77%-5.89M | -246.97%-42.65M | -101.14%-1.53M | -84.57%25.44M | 10.25%-10.21M | -698.66%-4.47M | 37.27%-12.29M |
| -Change in receivables | 86.84%-1.29M | -102.92%-582K | 61.05%-2.68M | 85.90%-1.71M | 134.23%3.68M | 49.31%-9.81M | 60.35%19.97M | 33.54%-6.88M | -17.83%-12.14M | 3.55%-10.76M |
| -Change in payables and accrued expense | -306.15%-9.09M | 88.00%-1.3M | -56.17%1.01M | -173.92%-8.82M | -97.82%21K | 4.78%4.41M | -350.05%-10.79M | 398.19%2.3M | 28.82%11.93M | 111.21%964K |
| -Change in other working capital | -476.20%-14.57M | 85.43%30.15M | 46.29%-3.02M | 209.11%4.65M | -1,756.35%-46.35M | -97.41%3.87M | -89.02%16.26M | -2,152.00%-5.63M | -338.85%-4.26M | -1,641.36%-2.5M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 0.63%-140.88M | -818.71%-14.68M | 6.23%-45.16M | -6.09%-43.76M | 31.47%-37.28M | -1,421.36%-141.77M | -98.48%2.04M | -6.55%-48.16M | -31.13%-41.25M | -16.89%-54.4M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 98.05%176.54M | 225.49%68.2M | 98.63%57.31M | -93.89%2.69M | 1,112.38%48.34M | 17.59%89.14M | 173.54%20.95M | -17.22%28.85M | -7.49%44.11M | -121.94%-4.78M |
| Net PPE purchase and sale | 84.13%-4.68M | 75.78%-827K | 97.11%-289K | 86.43%-1.22M | 66.98%-2.35M | -244.02%-29.5M | 14.97%-3.42M | -512.42%-10.01M | -405.64%-8.96M | -517.53%-7.11M |
| Net intangibles purchase and sale | 18.44%-199K | --0 | --0 | ---26K | ---173K | -17.87%-244K | 50.00%-13K | -507.89%-231K | --0 | --0 |
| Net business purchase and sale | --45.26M | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net investment purchase and sale | 13.59%135.03M | 182.25%68.81M | 46.38%57.22M | -178.89%-41.87M | 2,074.56%50.86M | 40.55%118.88M | 199.72%24.38M | 7.03%39.09M | 7.30%53.07M | -89.85%2.34M |
| Net other investing changes | --1.12M | --211K | --376K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 98.05%176.54M | 225.49%68.2M | 98.63%57.31M | -93.89%2.69M | 1,112.38%48.34M | 17.59%89.14M | 173.54%20.95M | -17.22%28.85M | -7.49%44.11M | -121.94%-4.78M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -93.16%880K | -94.73%74K | -58.95%596K | -99.86%14K | 460.00%196K | 291.33%12.87M | 2,598.08%1.4M | 944.60%1.45M | 289.27%9.98M | -93.45%35K |
| Net common stock issuance | -95.13%624K | -99.93%1K | -69.92%435K | --0 | --188K | 406.80%12.82M | --1.4M | 14,360.00%1.45M | --9.98M | --0 |
| Proceeds from stock option exercised by employees | 412.00%256K | 812.50%73K | 2,583.33%161K | 1,300.00%14K | -77.14%8K | -93.41%50K | -84.62%8K | -95.35%6K | -97.73%1K | -93.45%35K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -93.16%880K | -94.73%74K | -58.95%596K | -99.86%14K | 460.00%196K | 291.33%12.87M | 2,598.08%1.4M | 944.60%1.45M | 289.27%9.98M | -93.45%35K |
| Net cash flow | ||||||||||
| Beginning cash position | -27.73%109.6M | 15.31%93.07M | -19.42%80.2M | 33.08%121.44M | -27.73%109.6M | 146.68%151.67M | 80.83%80.71M | 80.67%99.52M | 146.40%91.26M | 146.68%151.67M |
| Current changes in cash | 191.88%36.54M | 119.68%53.6M | 171.37%12.74M | -419.86%-41.05M | 119.03%11.25M | -144.27%-39.77M | -76.87%24.4M | -74.89%-17.86M | -31.66%12.84M | -143.94%-59.14M |
| Effect of exchange rate changes | 138.15%877K | -92.21%350K | 113.51%129K | 95.84%-190K | 146.30%588K | -729.86%-2.3M | 191.31%4.49M | -297.92%-955K | -522.92%-4.57M | -522.55%-1.27M |
| End cash Position | 34.14%147.02M | 34.14%147.02M | 15.31%93.07M | -19.42%80.2M | 33.08%121.44M | -27.73%109.6M | -27.73%109.6M | 80.83%80.71M | 80.67%99.52M | 146.40%91.26M |
| Free cash flow | 15.01%-145.76M | -1,018.54%-15.5M | 22.17%-45.45M | 10.37%-45M | 35.29%-39.81M | -8,904.36%-171.51M | -101.07%-1.39M | -24.59%-58.4M | -51.05%-50.21M | -28.63%-61.52M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
